Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Pilot Study Probing the Antidepressant Effects of 0.5 mg/kg Intravenous Ketamine in Drug-resistant Depressed Patients (Unipolar Depression): Efficacy, Safety, Brain Function

To see complete record on, please visit this link

Id: NCT01135758

Organisation Name: University Hospital, Geneva

Overal Status: Terminated

Start Date: June 2010

Last Update: December 7, 2015

Lead Sponsor: Markus KOSEL

Brief Summary: Targeting the glutamatergic system to treat depression is a new and promising strategy based on studies at the molecular, synaptic, and neuronal level but also on results of studies conducted in animal models and first clinical studies involving depressed patients.Ketamine has been proposed as a novel approach to induce rapid antidepressant response. In this pilot project the investigators aim to introduce this novel and promising approach into clinical practice. Besides the assessment of clinical efficacy, the investigators will put a special emphasis on the assessment of ketamine-associated effects on brain function using fMRI and cognitive testing.

  • Major Depression

Total execution time in seconds: 0.21010994911194